Challenges of developing an ADA assay for bispecific antibody therapeutics and ADA characterization
3 March 2022
Bispecifics are biopharmaceutical products that bind to two different targets. In this application note, LGC describes the challenges of building anti-drug antibody (ADA) assays, and how to overcome these challenges. Download to explore how LGCs tiered approach provides validated assays that will support sample analysis throughout the method lifecycle.